| Literature DB >> 28490663 |
Kenneth A Mundt1, Linda D Dell1, Lori Crawford1, Alexa E Gallagher1.
Abstract
OBJECTIVE: To evaluate mortality risks of angiosarcoma of the liver (ASL), primary hepatocellular carcinoma (HCC) and other cancers among 9951 men employed between 1942 and 1972 at 35 US vinyl chloride (VC) or polyvinyl chloride plants followed for mortality through 31 December 2013.Entities:
Keywords: angiosarcoma of the liver; hepatocellular carcinoma; vinyl chloride
Mesh:
Substances:
Year: 2017 PMID: 28490663 PMCID: PMC5629943 DOI: 10.1136/oemed-2016-104051
Source DB: PubMed Journal: Occup Environ Med ISSN: 1351-0711 Impact factor: 4.402
Figure 1Liver cancer deaths included in each analysis. ASL, angiosarcoma of the liver; DC, death certificate; HCC, hepatocellular carcinoma; NCHS, National Center for Health Statistics; NIOSH, National Institute for Occupational Safety and Health.
Observed and expected deaths, SMRs and 95% CIs for selected causes* for 9951 vinyl chloride workers†
| Cause of death | Observed | Expected | SMR | 95% CI |
| All causes | 5636 | 6493.2 |
|
|
| All malignant neoplasms | 1713 | 1741.0 |
| 0.94 to 1.03 |
| Oral cavity and pharynx | 35 | 35.3 |
| 0.69 to 1.38 |
| Oesophagus | 55 | 48.6 |
| 0.85 to 1.47 |
| Stomach | 34 | 45.2 |
| 0.52 to 1.05 |
| Intestine except rectum | 115 | 140.2 |
|
|
| Rectum | 30 | 30.1 |
| 0.67 to 1.42 |
| Liver, biliary passages and gall bladder | 135 | 47.0 |
|
|
| Liver only‡ | 117 | 31.8 |
|
|
| Pancreas | 75 | 83.4 |
| 0.71 to 1.13 |
| Larynx | 12 | 21.5 |
|
|
| Trachea, bronchus, lung | 591 | 672.5 |
|
|
| Pleura | 4 | 1.2 |
| 0.92 to 8.63 |
| Breast | 3 | 2.0 |
| 0.30 to 4.28 |
| Prostate | 112 | 126.3 |
| 0.73 to 1.07 |
| Kidney | 52 | 44.6 |
| 0.87 to 1.53 |
| Bladder and other urinary organs | 55 | 45.7 |
| 0.91 to 1.57 |
| Bone | 4 | 4.7 |
| 0.23 to 2.17 |
| Melanoma | 29 | 26.7 |
| 0.73 to 1.56 |
| Skin | 7 | 8.9 |
| 0.32 to 1.63 |
| Mesothelioma | 12 | 5.2 |
|
|
| Connective tissue | 20 | 8.2 |
|
|
| Brain and central nervous system | 52 | 41.1 |
| 0.95 to 1.66 |
| Eye | 2 | 0.9 |
| 0.26 to 7.72 |
| Thyroid | 3 | 3.2 |
| 0.19 to 2.74 |
| Other and unspecified malignancy | 102 | 124.4 |
| 0.67 to 1.00 |
| Hodgkin’s disease | 3 | 8.1 |
| 0.08 to 1.08 |
| Non-Hodgkin’s lymphoma | 64 | 62.7 |
| 0.79 to 1.30 |
| Multiple myeloma | 25 | 27.9 |
| 0.58 to 1.32 |
| Leukaemia and aleukaemia | 71 | 63.3 |
| 0.88 to 1.41 |
| Benign and unspecified neoplasms | 13 | 21.1 |
| 0.33 to 1.06 |
| Diseases of blood and blood-forming organs | 17 | 24.7 |
| 0.40 to 1.10 |
| Diabetes | 130 | 150.8 |
| 0.72 to 1.02 |
| Nervous system and sense organs | 141 | 130.4 |
| 0.91 to 1.27 |
| Diseases of the heart | 1910 | 2225.6 |
|
|
| Cerebrovascular disease | 259 | 311.4 |
|
|
| Diseases of the respiratory system | 430 | 591.2 |
|
|
| Chronic obstructive pulmonary disease | 248 | 337.3 |
|
|
| Asbestosis | 6 | 2.4 |
| 0.92 to 5.51 |
| Diseases of the digestive system | 185 | 248.9 |
|
|
| Cirrhosis and other chronic liver disease | 97 | 113.5 |
| 0.69 to 1.04 |
| Diseases of genitourinary | 80 | 111.5 |
|
|
| Diseases of skin and subcutaneous tissue | 4 | 5.8 |
| 0.19 to 1.75 |
| Symptoms and ill-defined conditions | 50 | 62.4 |
| 0.59 to 1.06 |
| External causes | 335 | 451.7 |
|
|
*NIOSH state-specific referent rates used unless otherwise noted.
†401,524 person-years for full cohort of 9951 workers.
‡NCHS/CanQues state referent rates uses.
NCHS, National Center for Health Statistics; NIOSH, National Institute for Occupational Safety and Health.
Risk estimates for ASL, HCC and unspecified liver cancer by cumulative exposure from Cox regression models
| ASL, n=63 | HCC, n=32 | Unspecified liver cancer, n=36 | |||||||
| n | HR | 95% CI | n | HR | 95% CI | n | HR | 95% CI | |
| Cumulative exposure (low cut-points)* | |||||||||
| <63 ppm-years | 3 |
| 4 |
| |||||
| 63 to <287 ppm-years | 3 |
| 0.2 to 5.1 | 3 |
| 0.2 to 3.5 | |||
| 287 to <865 ppm-years | 4† |
| 1 |
| 0.03 to 3.0 | 5 |
| 0.3 to 4.4 | |
| 865 to <2271 ppm-years | 9 |
|
| 4 |
| 0.3 to 5.1 | 6 |
| 0.4 to 4.6 |
| ≥2271 ppm-years | 50 |
|
| 21 |
|
| 18 |
|
|
| Cumulative exposure (high cut-points)‡ | |||||||||
| <1021 ppm-years | 6 |
| 8 |
| 13 |
| |||
| 1021 to <3301 ppm-years | 12 |
|
| 4 |
| 0.4 to 3.8 | 7 |
| 0.5 to 3.2 |
| 3301 to <5686 ppm-years | 11 |
|
| 7 |
|
| 9 |
|
|
| 5686 to <10 551 ppm-years | 18 |
|
| 6 |
|
| 4 |
| 1.0 to 9.7 |
| ≥10 551 ppm-years | 16 |
|
| 7 |
|
| 3 |
|
|
*Low cut-points are based on quintiles of cumulative exposure for the entire cohort.
†Due to zero cases in the referent group, one case in the second quintile and three in the third quintile, the first three quintiles have been collapsed to form a single referent category.
‡High cut-points are based on quintiles of cumulative exposure for all liver cancers in the entire cohort.
ASL, angiosarcoma of the liver; HCC, hepatocellular carcinoma; Ref, referent.
Figure 2HR for ASL and HCC by deciles of cumulative exposure, based on the exposure distribution of all liver cancer cases. ASL, angiosarcoma of the liver; HCC, hepatocellular carcinoma; ppm, parts per million-years.
Mortality from selected causes of death by categories of cumulative exposure* to vinyl chloride from Cox regression models†
| Melanoma, n=29 | Brain cancer, n=52 | Lung cancer, n=591 | NHL, n=64 | |||||||||
| n | HR | 95% CI | n | HR | 95% CI | n | HR | 95% CI | N | HR | 95% CI | |
| Cumulative exposure* | ||||||||||||
| <63 ppm-years | 5 |
| – | 13 |
| – | 96 |
| – | 14 |
| – |
| 63 to <287 ppm-years | 8 |
| 0.5 to 5.1 | 13 |
| 0.5 to 2.3 | 123 |
| 1.0 to 1.7 | 8 |
| 0.3 to 1.4 |
| 287 to <865 ppm-years | 5 |
| 0.3 to 3.3 | 12 |
| 0.4 to 2.0 | 128 |
| 1.0 to 1.7 | 9 |
| 0.3 to 1.4 |
| 865 to <2271 ppm-years | 4 |
| 0.2 to 2.6 | 6 |
| 0.2 to 1.2 | 118 |
| 0.9 to 1.5 | 14 |
| 0.4 to 1.9 |
| ≥2271 ppm-years | 7 |
| 0.4 to 3.6 | 8 |
| 0.3 to 1.4 | 126 |
| 0.9 to 1.5 | 19 |
| 0.6 to 2.3 |
| Connective and soft tissue cancers, n=20 | Cirrhosis of the liver, n=97 | NMRD, n=430 | COPD, n=248 | |||||||||
| n |
| 95% CI | n |
| 95% CI | n |
| 95% CI | n |
| 95% CI | |
| Cumulative exposure* | ||||||||||||
| <63 ppm-years | 1 |
| – | 11 |
| – | 62 |
| – | 35 |
| – |
| 63 to <287 ppm-years | 1 |
| 0.1 to 16.7 | 19 |
| 0.9 to 3.8 | 85 |
| 1.0 to 2.0 | 56 |
| 1.1 to 2.5 |
| 287 to <865 ppm-years | 3 |
| 0.3 to 28.0 | 22 |
| 1.0 to 4.1 | 93 |
| 1.0 to 1.9 | 59 |
| 1.0 to 2.4 |
| 865 to <2271 ppm-years | 5 |
| 0.5 to 39.5 | 24 |
| 1.0 to 4.3 | 100 |
| 1.0 to 1.9 | 52 |
| 0.8 to 1.9 |
| ≥2271 ppm-years | 10 |
|
| 21 |
| 0.9 to 3.7 | 90 |
| 0.8 to 1.5 | 46 |
| 0.6 to 1.5 |
*Quintiles of cumulative exposure based on distributions among the full cohort, n=9951.
†All models unadjusted.
COPD, chronic obstructive pulmonary disease; NHL, non-Hodgkin’s lymphoma; NMRD, non-malignant respiratory disease; ppm, parts per million; Ref, referent.